AI-designed IPF drug advances to Phase III

Insilico’s rentosertib enters late-stage testing, bringing an aging-informed approach to one of medicine’s most challenging fibrotic diseases. Insilico Medicine has initiated a Phase III clinical program for rentosertib, its investigational TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), marking the latest milestone for a drug that has become one of the most closely watched programmes in […] The post AI-designed IPF drug advances to Phase III appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.